Portrait of Serene Cai Huiting
Photo: Courtesy Serene Cai via Forbes profile · Publisher-directed editorial display; source copyright retained

FigureAsia 35 Under 35 · Healthcare

Serene Cai Huiting

Age 34 · Home-based care and telehealth · Singapore

Physician-founder whose platform reports more than 300,000 home visits, over 500 licensed clinicians and partnerships with more than 20 hospitals across two countries.

Approximate age at 31 December 2025
34
Field
Healthcare
Country or region
Singapore
FigureAsia U35 Assessment
88.0 / 100

Career and documented record

Serene Cai has helped build a care model around a simple observation: many patients need clinical attention but do not need to begin in a hospital. By 2025–2026, the service she cofounded reported more than 300,000 home visits, over 500 licensed clinicians and more than 20 hospital partners across Singapore and Malaysia. Cai also contributed to Singapore's 2025 policy discussion on how telehealth should be governed and integrated.

The operational contribution is the connective layer — clinician dispatch, remote assessment, diagnostics, medication and escalation — rather than a video call in isolation. Cai's operating role gives her direct responsibility for how that pathway connects logistics, continuity and hospital standards; clinical decisions remain with licensed professionals. The model has particular relevance to older adults, post-discharge patients and families for whom travel is itself a barrier.

Scale figures are company-reported and do not establish that every home visit prevented an admission or improved an outcome. The platform's quality must be judged by clinical governance, escalation and comparative evidence as it grows. Cai's inclusion recognizes the creation of a substantial Southeast Asian home-care network and her role in shaping the policy environment around it.

Why Serene Cai Huiting is on the list

FigureAsia selected Cai because she has combined delivery at scale with participation in public policy. Her work treats the home as part of the health system and has built links to hospitals rather than positioning telehealth as a substitute for them. The score is moderated by the provenance of operating metrics and limited published outcome comparisons; it rewards infrastructure, reach and operating agency.

The 2025–26 record

Principal milestone

More than 300,000 home visits reported

Evidence record

More than 500 licensed clinicians

Scale or implementation

More than 20 hospital partners across two countries

The work in its field

Within home-based care and telehealth, the relevant test is whether a result can survive scrutiny of maturity, attribution, validity and practical fit. That distinction matters: completed evidence is not projected benefit, and individual responsibility is not interchangeable with the wider team’s achievement.

Assessment breakdown

88.0out of 100

01

Substantive 2025–2026 contribution

18 / 20

The score reflects completed 2025–26 work in home-based care and telehealth, assessed at the documented maturity of deployed home-care and telehealth network.

02

Verified impact

12 / 15

Impact credit is limited to the measured study, regulatory, implementation or operating record stated in the profile; unsupported patient benefit is excluded.

03

Originality and distinction

8 / 10

The work creates or materially advances a distinctive capability within home-based care and telehealth rather than relying on title or institutional association.

04

Field and industry influence

9 / 10

The assessment recognises demonstrated effects on research, product development, care delivery or professional practice, with publicity alone carrying no weight.

05

Individual agency

10 / 10

Named authorship and the documented role of Cofounder establish individual responsibility while preserving credit for collaborators.

06

Durability and trajectory

4.5 / 5

The cited work forms part of a continuing programme, platform or research trajectory rather than a single uncompleted announcement.

07

Asian significance and global relevance

5 / 5

The Asian connection is material to the person's identity, operating base or populations served: Singaporean physician-founder.

08

Clinical and scientific validity

4.9 / 7

Clinical and scientific validity is calibrated to deployed home-care and telehealth network, with the profile retaining the evidence boundary attached to the result.

09

Safety, quality and responsible governance

5.6 / 7

Safety and governance credit reflects accurate regulatory language, study limitations, data stewardship and the refusal to turn early evidence into clinical certainty.

10

Translation and care-pathway fit

6 / 6

The work is scored for its demonstrated fit with a laboratory, regulatory, clinical, operational or public-health pathway, not for projected future adoption.

11

Access, equity and resource stewardship

5 / 5

Access credit reflects documented reach, capacity, affordability or inclusion while distinguishing service volume from proven clinical outcome.

Evidence and attribution

Material claims on this page are supported by the edition’s evidence record. FigureAsia tests age, identity, role, result and individual attribution before publication. Public profiles present the reported record; supporting documentation is retained for accuracy review and corrections.

Achievement records
4
Assessment window
2025–26
Editorial status
Included in the 2026 FigureAsia 35 Under 35 edition

Rights and credit

The portrait is published under the rights basis recorded for this edition. Third-party ownership and reuse restrictions remain in force.

Publication status
Published under a documented rights basis
Credit
Courtesy Serene Cai via Forbes profile
Licence
Publisher-directed editorial display; source copyright retained
Portrait source and credit